#1 Clinical Trials Search in Europe

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

3 1 1 1

What is this study about?

This clinical trial is focused on studying a type of lung cancer known as Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). The study is investigating the effects of two treatments: lurbinectedin and atezolizumab. Atezolizumab, also known by its code name RO5541267, is a medication that is already used in treating this type of cancer. Lurbinectedin, with the code name RO7508182, is being tested in combination with atezolizumab to see if it can improve outcomes for patients.

The purpose of the study is to compare the effectiveness of using lurbinectedin together with atezolizumab against using atezolizumab alone as a maintenance therapy. Maintenance therapy is a treatment given to help keep cancer from coming back after it has responded to initial treatment. Participants in the study will have already received a first round of treatment with atezolizumab, carboplatin, and etoposide, which are standard drugs used to treat ES-SCLC.

During the study, participants will be randomly assigned to receive either the combination of lurbinectedin and atezolizumab or atezolizumab alone. The study will monitor how long participants live without their cancer getting worse and their overall survival. The trial will also look at the safety of the treatments and any side effects that may occur. This study aims to provide more information on whether the combination of these drugs can offer better outcomes for patients with this type of lung cancer.

1 joining the study

Upon joining the study, participation is confirmed for individuals with extensive-stage small-cell lung cancer (ES-SCLC) who meet specific criteria, such as having a confirmed diagnosis and adequate organ function.

2 randomization

Participants are randomly assigned to one of two groups: one receiving a combination of lurbinectedin and atezolizumab, and the other receiving atezolizumab alone as maintenance therapy.

3 treatment administration

The treatment involves intravenous infusion of the medications. Atezolizumab is administered as a 1,200 mg concentrate for solution, while lurbinectedin is also given via infusion. The frequency and duration of administration are determined by the study protocol.

4 monitoring and assessments

Participants undergo regular monitoring to assess the progression-free survival and overall survival. This includes evaluations by an independent review facility and investigators using specific criteria.

5 evaluation of treatment response

The response to treatment is evaluated based on progression-free survival, overall survival, and other measures such as objective response rate and duration of response.

6 adverse events monitoring

The incidence and severity of any adverse events are closely monitored, with severity determined according to established criteria.

7 completion of study

The study is estimated to conclude by March 2026, with ongoing assessments and data collection throughout the trial period.

Who Can Join the Study?

  • Must have a confirmed diagnosis of Small-Cell Lung Cancer (SCLC), which is a type of lung cancer.
  • Must have adequate hematologic and end-organ function, meaning the blood and organs are working well enough.
  • Must have an ECOG PS of 0 or 1, which is a scale used to measure how well a person can perform daily activities. A score of 0 means fully active, and 1 means some symptoms but still able to do light work.
  • Must not have had any prior systemic treatment for ES-SCLC, which means no previous treatments that affect the whole body for this type of cancer.
  • Must have an ongoing response or stable disease according to RECIST v1.1, which is a set of rules to measure how well a cancer treatment is working.
  • Any side effects from previous cancer treatments or PCI (a type of brain radiation) must have improved to a mild level, known as Grade 1 or better.
  • Both males and females can participate.
  • Participants can be from a vulnerable population, meaning they might need extra protection or care.

Who Cannot Join the Study?

  • Patients who have a different type of cancer other than Small-Cell Lung Cancer (SCLC) cannot participate. SCLC is a specific type of lung cancer.
  • Patients who are not within the specified age range for the study cannot participate. The study has specific age requirements.
  • Patients who are not able to follow the study procedures or attend the required visits cannot participate.
  • Patients who have other serious health conditions that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have participated in another clinical trial recently may not be eligible.
  • Patients who have allergies or reactions to the study medications cannot participate.
  • Patients who have not recovered from major surgery or a serious illness cannot participate.
  • Patients who have a history of drug or alcohol abuse that might affect the study cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Koranyi National Institute For Pulmonology Budapest Hungary
Katholieke Universiteit te Leuven Leuven Belgium

Other Sites

Site Name City Country Status
Institut Jules Bordet Anderlecht Belgium
Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie Olsztyn Poland
Istituto Europeo Di Oncologia S.r.l. Milan Italy
Asklepios Klinik Gauting GmbH Gauting Germany
Hospital Universitario 12 De Octubre Madrid Spain
Hospital Del Mar Barcelona Spain
HELIOS Klinikum Emil von Behring GmbH Berlin Germany
Vitaz Sint-Niklaas Belgium
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet Szolnok Hungary
Azienda Sociosanitaria 3 Genoa Italy
Martha-Maria Krankenhaus Halle-Doelau gGmbH Halle (Saale) Germany
Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH Berlin Germany
LungenClinic Grosshansdorf GmbH Grosshansdorf Germany
Henry Dunant Hospital Center Athens Greece
Universitaetsklinikum Schleswig-Holstein AöR Kiel Germany
General University Hospital Of Larissa Larissa Greece
Virgen del Rocío University Hospital Sevilla Spain
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Klinikum Chemnitz gGmbH Chemnitz Germany
Jessa Ziekenhuis Hasselt Belgium
Tuedogyogyintezet Toeroekbalint Torokbalint Hungary
St. Luke’s Hospital S.A. Thessaloniki Greece
Wielkopolskie Centrum Pulmonologii I Torakochirurgii Im. Eugenii I Janusza Zeylandow Poznan Poland
University Of Pecs Pecs Hungary
Azienda Unita Sanitaria Locale Della Romagna Faenza Italy
Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur Namur Belgium
Hospital Universitario Virgen De La Victoria Malaga Spain
Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy Otwock Poland
Ernefla Mechelen Belgium
Lrvji Gknebqw Hbmxdgbf Oj Apllle Athens Greece
Aaoienm Oxwswrqbofh Uleluvbrdfifp Ohiavqxv Rpnjwvm Foggia Italy
Askwaa Mxxknrs Cpygcn Snbm Thessaloniki Greece
Naxtoxxb Ibaddbpv Ougffynwj Igm Mlmnm Sengvbmtzchedvzbdkwqbuxrdlsb Ihtgohgf Bmxyrjin Cracow Poland
Ujjfysmjehblgb Crkceew Kgegpzgql Gdansk Poland
Hpvokthe Dt Lv Sashw Csif I Sdyv Pkw Barcelona Spain
Kxfxcsve Etkcskrhbgsxvosqxdgronkq Hkkncexkstjzgemyt Essen Germany
Hpqeiixz Vhmm dvuahjwl Barcelona Spain
Hetlievz Udxyaeggrdvug dk A Cuadoc A Coruna Galicia Spain
Kmvvczizj Sbkayox Svhxnlneroprios im Jkoz Pqjny Ix Cracow Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
23.02.2022
Germany Germany
Not recruiting
23.02.2022
Greece Greece
Not recruiting
23.02.2022
Hungary Hungary
Not recruiting
23.02.2022
Italy Italy
Not recruiting
23.02.2022
Poland Poland
Not recruiting
23.02.2022
Spain Spain
Not recruiting
23.02.2022

Trial locations

Investigated drugs:

Lurbinectedin is a medication being studied for its potential to treat extensive-stage small-cell lung cancer. It is being tested in combination with another medication to see if it can help improve the outcomes for patients who have already received initial treatment.

Atezolizumab is an immunotherapy drug that helps the body’s immune system fight cancer cells. In this study, it is used both alone and in combination with lurbinectedin to see how effective it is in maintaining the health of patients with extensive-stage small-cell lung cancer after they have received their first round of treatment.

Carboplatin is a chemotherapy drug that is used to kill cancer cells. It is part of the initial treatment given to patients in this study before they receive maintenance therapy.

Etoposide is another chemotherapy medication used alongside carboplatin in the initial treatment phase. It works by preventing cancer cells from dividing and growing.

Investigated diseases:

Small-Cell Lung Cancer (SCLC) – This is a fast-growing type of lung cancer that primarily arises in the bronchi, the main airways of the lungs. It is characterized by small cells that multiply quickly and form large tumors. SCLC often spreads rapidly to other parts of the body, including the lymph nodes, liver, bones, adrenal glands, and brain. The disease is strongly associated with smoking and is less common than non-small cell lung cancer. Symptoms may include coughing, chest pain, shortness of breath, and weight loss. Due to its aggressive nature, SCLC is often diagnosed at an advanced stage.

Trial ID:
2023-503868-16-00
Protocol code:
GO43104
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

    Recruiting

    2 1 1
    Investigated drugs:
    France Greece Italy Spain

  • A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

    Recruiting

    4 1 1 1
    Investigated drugs:
    France Germany Italy Spain